These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


244 related items for PubMed ID: 36045702

  • 1. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
    Aimar G, Paratore C, Zichi C, Marino D, Sperti E, Caglio A, Gamba T, De Vita F, Di Maio M.
    Explor Target Antitumor Ther; 2021; 2(5):448-464. PubMed ID: 36045702
    [Abstract] [Full Text] [Related]

  • 2. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M, Heumann T, Goff L, Agarwal R.
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [Abstract] [Full Text] [Related]

  • 3. Current options and future directions of systemic therapy for advanced biliary tract cancer.
    Prete MG, Cammarota A, D'Alessio A, Zanuso V, Rimassa L.
    Explor Target Antitumor Ther; 2021 Apr; 2(5):416-433. PubMed ID: 36045701
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cell of origin in biliary tract cancers and clinical implications.
    Moeini A, Haber PK, Sia D.
    JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
    [Abstract] [Full Text] [Related]

  • 6. Treating Biliary Tract Cancers: New Targets and Therapies.
    Ho J, Fiocco C, Spencer K.
    Drugs; 2022 Nov; 82(17):1629-1647. PubMed ID: 36441502
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.
    Chakrabarti S, Kamgar M, Mahipal A.
    Cancers (Basel); 2020 Jul 24; 12(8):. PubMed ID: 32722188
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L, Berger AW, Beutel AK, Gallmeier E, Angermeier S, Fischer von Weikersthal L, Goetze TO, Muche R, Seufferlein T, Ettrich TJ.
    BMC Cancer; 2019 Oct 23; 19(1):990. PubMed ID: 31646981
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
    Chang YT, Chang MC, Huang KW, Tung CC, Hsu C, Wong JM.
    J Gastroenterol Hepatol; 2014 May 23; 29(5):1119-25. PubMed ID: 24372748
    [Abstract] [Full Text] [Related]

  • 15. Precision Oncology Targets in Biliary Tract Cancer.
    Farha N, Dima D, Ullah F, Kamath S.
    Cancers (Basel); 2023 Mar 31; 15(7):. PubMed ID: 37046766
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Integrating Molecular Insights into Biliary Tract Cancer Management: A Review of Personalized Therapeutic Strategies.
    Ros-Buxó M, Mauro E, Sauri T, Iserte G, Fuster-Anglada C, Díaz A, Sererols-Viñas L, Affo S, Forner A.
    Curr Oncol; 2024 Jun 21; 31(7):3615-3629. PubMed ID: 39057138
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 13.